Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ORNBV | Helsinki | EUR | Real-time | |
ORNAV | Helsinki | EUR | Real-time | |
ORNBVh | BATS Europe | EUR | Delayed | |
ORINY | OTC Markets | USD | Delayed | |
0M2O | London | EUR | Real-time | |
1ORNBV | Milan | EUR | Real-time |
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. Further, the company has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal’s generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.
Name | Age | Since | Title |
---|---|---|---|
Hilpi Rautelin | 61 | 2017 | Independent Vice Chairman of the Board |
Maziar Mike Doustdar | 52 | 2022 | Independent Director |
Karen Lykke Sorensen | 60 | 2022 | Independent Director |
Kari Jussi Aho | 64 | 2020 | Independent Director |
Mikael Silvennoinen | 68 | 2014 | Independent Director |
Eija Ronkainen | 58 | 2016 | Independent Director |
Ari Tapio Lehtoranta | 61 | 2017 | Independent Director |
Veli-Matti Johannes Mattila | 63 | 2021 | Independent Chairman |
Henrik Stenqvist | 57 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review